Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus plus exemestane versus everolimus alone versus capecitabine in postmenopausal ER-positive advanced breast cancer
2012-003757-28Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2013
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus, exemestane, capecitabine in breast cancer, sponsored by Novartis. Started Jan 2013; status: completed.
02
Drugs
everolimusexemestanecapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2012-003757-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003757-28.